Wednesday, February 10, 2010, 1:27PM AEST - The Australian Stockmarket closes in 2 hours and 38 minutes.
To create a watchlist or portfolio of shares, Register

Anadys Pharmaceuticals Inc. (ANDS)

8:00AM AEST: 2.22 USD  Up 0.01 (0.45%)  
 MORE ON ANDS 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Anadys Pharmaceuticals, Inc. (NGM:ANDS) Delayed quote dataEdit
Last Trade:2.22 USD
Trade Time: 8:00AM AEST
Change:Up 0.01 (0.45%)
Prev Close:2.21
Open:2.21
Bid:N/A
Ask:2.30 x 700
1y Target Est:5.06
Day's Range:2.15 - 2.32
52wk Range:1.44 - 8.43
Volume:502,057
Avg Vol (3m):596,864
Market Cap:82.83M
P/E (ttm):N/A
EPS (ttm):-1.00
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add ANDS to Portfolio   Download Data

 HEADLINES 
Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
PR Newswire (Wed, Feb 3)
Anadys Pharmaceuticals Provides Progress Update on Phase II Study of ANA598 in Hepatitis C Patients
PR Newswire (Fri, Jan 22)
Nexen, Anadys Options Lure Bullish Traders
at TheStreet.com (Tue, Jan 12)
Monday Options Update: NDAQ, ANDS, F & EEM
at Seeking Alpha (Tue, Jan 12)
Anadys Drug Meets Key Study Goals
Zacks.com (Sat, Dec 19)
StockPreacher Initiates Independent Research Coverage for Anadys Pharmaceuticals Inc.
GlobeNewswire (Fri, Dec 18)
Anadys hepatitis C drug meets key study goals
AP (Fri, Dec 18)
Sequenom, Delta Petroleum: Early Volume Plays
at TheStreet.com (Fri, Dec 18)
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
PR Newswire (Thu, Dec 17)
Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
PR Newswire (Wed, Nov 25)
ANADYS PHARMACEUTICALS INC Financials
EDGAR Online Financials (Fri, Nov 6)
ANADYS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Sat, Oct 31)
More Headlines for ANDS...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.89
EPS Est (in 2 years) (Dec-10) :-0.61
Avg Rec (current)*:1.5
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology. It develops ANA598, a small-molecule non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatiti...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices